IPP Bureau
Shilpa Medicare receives NoC for biosimilar Aflibercept
By IPP Bureau - April 25, 2022
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Glamyo Health records ARR of US $ 8 million last fiscal
By IPP Bureau - April 25, 2022
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
GOQii to foray into UK patient care with GBP 10 million investment
By IPP Bureau - April 25, 2022
Partnership with Modality, award-winning GP super partnership
Porton Advanced and Sinorda Biomedicine collaborate for cell therapy development for solid tumours
By IPP Bureau - April 25, 2022
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
New studies presented at ECCMIC 2022 confirm benefit of remdesivir in treating Covid-19
By IPP Bureau - April 25, 2022
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Erytech sells U.S. manufacturing facility and enters long-term supply agreement with Catalent
By IPP Bureau - April 25, 2022
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Malaria cases and related deaths have reduced significantly: Dr Mansukh Mandaviya
By IPP Bureau - April 25, 2022
April 25th is commemorated as World Malaria Day
Doctors at Yashoda successfully treated advanced-stage laryngeal cancer
By IPP Bureau - April 25, 2022
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
Marskans Pharma acquires Dubai based Access Healthcare
By IPP Bureau - April 25, 2022
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
Thermo Fisher opens bioprocessing manufacturing site in Ogden, Utah
By IPP Bureau - April 25, 2022
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
NovoSeven recommended for approval for the treatment of severe postpartum haemorrhage by the European Medicines Agency
By IPP Bureau - April 23, 2022
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Twenty eight companies commit to Rs 6000 crore at Global Ayush meet
By IPP Bureau - April 23, 2022
The commitment is expected to generate over 5.56 lakh jobs and positively impact the lives of more than 76 lakh people, the ministry said
CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment
By IPP Bureau - April 23, 2022
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
CHMP adopts positive opinion on Tabrecta for advanced non-small cell lung cancer
By IPP Bureau - April 23, 2022
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Novavax initiates Covid-19 booster study in adolescents in Phase 3 trial
By IPP Bureau - April 23, 2022
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
